secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001104659-25-028226
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway
--------------------------------------------------------------------------------

- Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.
- Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.
- FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.
- Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.
- Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/0001104659-25-028226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer